Eric T. Gangl
AstraZeneca (South Korea)(KR)AstraZeneca (Netherlands)(NL)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Estrogen and related hormone effects, Immune cells in cancer, Synthesis and Catalytic Reactions, Mast cells and histamine, Cytokine Signaling Pathways and Interactions
Most-Cited Works
- → Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia(2018)480 cited
- Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir.(1998)
- → Reduction of Signal Suppression Effects in ESI-MS Using a Nanosplitting Device(2001)180 cited
- → Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist(2020)109 cited
- → Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy(2021)90 cited
- → Structural elucidation of metabolites of ritonavir and indinavir by liquid chromatography–mass spectrometry(2002)79 cited
- →